IHS Chemical Week

EnviroTech :: Regulatory

FDA Criticized for Negligence in Baxter Heparin Case

4:25 PM MST | March 3, 2008 | Deepti Ramesh

The U.S. FDA has been heavily criticized by Congress for not inspecting a plant in China that manufactures the active pharmaceutical ingredient (API) for heparin, a blood-thinning drug made by Baxter International (Deerfield, IL). Heparin has caused four deaths and had other harmful effects on a growing number of patients in the U.S. FDA confused the identity of the company that operates the Chinese API plant with that of another company with a similar name, when the API manufacturer applied for approval of its facility, reports say. The other company had been...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa